• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从类天然产物文库中发现并优化非甾体类法尼醇X受体激动剂

Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.

作者信息

Nicolaou K C, Evans Ronald M, Roecker A J, Hughes Robert, Downes Michael, Pfefferkorn Jeffery A

机构信息

Department of Chemistry, Skaggs Institute for Chemical Biology, Scripps Research Institute, Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, USA.

出版信息

Org Biomol Chem. 2003 Mar 21;1(6):908-20.

PMID:12929628
Abstract

The efficient regulation of cholesterol biosynthesis, metabolism, acquisition, and transport is an essential component of lipid homeostasis. The farnesoid X receptor (FXR) is a transcriptional sensor for bile acids, the primary product of cholesterol metabolism. Accordingly, the development of potent, selective, small molecule agonists, partial agonists, and antagonists of FXR would be an important step in further deconvoluting FXR physiology. Herein, we describe the development of four novel classes of potent FXR activators originating from natural product-like libraries. Initial screening of a 10,000-membered, diversity-orientated library of benzopyran containing small molecules for FXR activation utilizing a cell-based reporter assay led to the identification of several lead compounds possessing low micromolar activity (EC50's = 5-10 microM). These compounds were systematically optimized employing parallel solution-phase synthesis and solid-phase synthesis to provide four classes of compounds that potently activate FXR. Two series of compounds, bearing stilbene or biaryl moieties, contain members that are the most potent FXR agonists reported to date in cell-based assays. These compounds may find future utility as chemical tools in studies aimed at further defining the physiological role of FXR and discovering potential therapeutic agents for the treatment of diseases linked to cholesterol and bile acid metabolism and homeostasis.

摘要

胆固醇生物合成、代谢、摄取及转运的有效调节是脂质稳态的重要组成部分。法尼酯X受体(FXR)是胆固醇代谢的主要产物——胆汁酸的转录传感器。因此,开发强效、选择性的FXR小分子激动剂、部分激动剂和拮抗剂将是进一步阐明FXR生理学的重要一步。在此,我们描述了源自类天然产物文库的四类新型强效FXR激活剂的开发。利用基于细胞的报告基因检测法,对一个包含10000个成员的、以多样性为导向的含苯并吡喃小分子文库进行FXR激活的初步筛选,鉴定出了几种具有低微摩尔活性(EC50 = 5 - 10 microM)的先导化合物。通过平行溶液相合成和固相合成对这些化合物进行系统优化,得到了四类能有效激活FXR的化合物。带有二苯乙烯或联芳基部分的两个系列化合物包含了在基于细胞的检测中迄今报道的最有效的FXR激动剂成员。这些化合物未来可能作为化学工具,用于进一步确定FXR生理作用以及发现与胆固醇和胆汁酸代谢及稳态相关疾病潜在治疗药物的研究中。

相似文献

1
Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.从类天然产物文库中发现并优化非甾体类法尼醇X受体激动剂
Org Biomol Chem. 2003 Mar 21;1(6):908-20.
2
Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.吡唑烷-3,5-二酮衍生物作为法尼醇X受体的强效非甾体激动剂:虚拟筛选、合成及生物学评价
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5497-502. doi: 10.1016/j.bmcl.2008.09.027. Epub 2008 Sep 10.
3
Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.胆汁酸衍生物作为法尼醇X受体的配体。鹅去氧胆酸一系列主体和侧链修饰类似物的合成、评价及构效关系
J Med Chem. 2004 Aug 26;47(18):4559-69. doi: 10.1021/jm049904b.
4
The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes.胆汁酸的核受体FXR可反式激活人类有机溶质转运蛋白α和β基因。
Am J Physiol Gastrointest Liver Physiol. 2006 Mar;290(3):G476-85. doi: 10.1152/ajpgi.00430.2005. Epub 2005 Nov 3.
5
Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.ATP8B1表达的敲低导致HepG2细胞中胆汁酸传感器FXR的特异性下调:FXR激动剂GW4064的作用。
Am J Physiol Gastrointest Liver Physiol. 2009 May;296(5):G1119-29. doi: 10.1152/ajpgi.90371.2008. Epub 2009 Feb 19.
6
The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.法尼醇X受体(FXR)作为非酒精性脂肪性肝炎的新靶点。
Diabetes Metab. 2008 Dec;34(6 Pt 2):685-91. doi: 10.1016/S1262-3636(08)74605-6.
7
5Alpha-bile alcohols function as farnesoid X receptor antagonists.
Biochem Biophys Res Commun. 2006 Jan 6;339(1):386-91. doi: 10.1016/j.bbrc.2005.11.027. Epub 2005 Nov 14.
8
3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists.借助分子对接对一系列非甾体类法尼醇X受体激动剂进行的3D-QSAR研究。
Bioorg Med Chem Lett. 2007 Apr 15;17(8):2156-60. doi: 10.1016/j.bmcl.2007.01.079. Epub 2007 Jan 31.
9
Identification of farnesoid X receptor modulators by a fluorescence polarization-based interaction assay.基于荧光偏振相互作用分析鉴定法尼醇 X 受体调节剂。
Anal Biochem. 2010 Mar 15;398(2):185-90. doi: 10.1016/j.ab.2009.11.008. Epub 2009 Nov 12.
10
Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.法尼醇X受体调节肾脏脂质代谢、纤维化和糖尿病肾病。
Diabetes. 2007 Oct;56(10):2485-93. doi: 10.2337/db06-1642. Epub 2007 Jul 27.

引用本文的文献

1
Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists.用于发现新型法尼醇X受体(FXR)激动剂的药效团建模与虚拟筛选研究
RSC Adv. 2021 Jan 7;11(4):2158-2166. doi: 10.1039/d0ra09320c. eCollection 2021 Jan 6.
2
Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists.非胆汁酸 FXR/TGR5 双重激动剂的发现、优化和评估。
Sci Rep. 2021 Apr 28;11(1):9196. doi: 10.1038/s41598-021-88493-0.
3
Perspectives from nearly five decades of total synthesis of natural products and their analogues for biology and medicine.
近五十年天然产物及其类似物的全合成及其在生物学和医学中的应用的观点。
Nat Prod Rep. 2020 Nov 1;37(11):1404-1435. doi: 10.1039/d0np00003e. Epub 2020 Apr 22.
4
Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts.新型法尼醇 X 受体激动剂的合成及其在激活小鼠骨髓间充质干细胞向成骨细胞分化中的功效验证。
Molecules. 2019 Nov 16;24(22):4155. doi: 10.3390/molecules24224155.
5
Nuclear Receptors Regulate Intestinal Inflammation in the Context of IBD.核受体在炎症性肠病背景下调节肠道炎症。
Front Immunol. 2019 May 14;10:1070. doi: 10.3389/fimmu.2019.01070. eCollection 2019.
6
Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking.基于6-ECDCA结合特性,通过虚拟筛选和分子对接发现新型FXR激动剂。
Medchemcomm. 2018 Jul 4;9(10):1630-1638. doi: 10.1039/c8md00272j. eCollection 2018 Oct 1.
7
Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.调节肠道胆汁酸/法尼醇 X 受体/成纤维细胞生长因子 15 轴可改善小鼠的酒精性肝病。
Hepatology. 2018 Jun;67(6):2150-2166. doi: 10.1002/hep.29676. Epub 2018 Apr 16.
8
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.基于时间分辨荧光共振能量转移的法尼醇 X 受体拮抗剂发现的分析方法的建立。
Bioorg Med Chem. 2013 Jul 15;21(14):4266-78. doi: 10.1016/j.bmc.2013.04.069. Epub 2013 May 7.
9
A Mast Cell Degranulation Screening Assay for the Identification of Novel Mast Cell Activating Agents.一种用于鉴定新型肥大细胞活化剂的肥大细胞脱颗粒筛选试验。
Medchemcomm. 2013 Jan 1;4(1). doi: 10.1039/C2MD20073B.
10
Constructing molecular complexity and diversity: total synthesis of natural products of biological and medicinal importance.构建分子复杂性和多样性:生物和医学重要性天然产物的全合成。
Chem Soc Rev. 2012 Aug 7;41(15):5185-238. doi: 10.1039/c2cs35116a. Epub 2012 Jun 28.